A comparative efficacy study: treatments of non-healing diabetic foot ulcers

比较疗效研究：治疗不愈合的糖尿病足溃疡

• 批准号: 8958773
• 负责人: Roslyn Rivkah ISSEROFF
• 金额: --
• 依托单位: VA NORTHERN CALIFORNIA HEALTH CARE SYS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-10-01 至 2017-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8958773
• 关键词: Address; Adult; Affect; Amputation; Apligraf; Biological; Biomedical Engineering; Biometry; Blood Vessels; California; Caring; Cells; Chronic; Clinic; Clinical; Clinical Research; Clinical Trials; Control Groups; Cost Analysis; Debridement; Devices; Diabetes Mellitus; Diabetic Foot; Diabetic Foot Ulcer; Diabetic ulcer; Effectiveness; Elements; Enrollment; Extracellular Matrix; FDA approved; Fibroblasts; Foot Ulcer; Genetic; Goals; Healed; Health; Health Care Costs; Health Expenditures; Healthcare; Healthcare Systems; Home environment; Immunologics; Improve Access; Incidence; Individual; Infection; Life; Limb structure; Living Costs; Marketing; Mind; Morbidity - disease rate; Neuropathy; Operative Surgical Procedures; Patient Care; Patient Recruitments; Patient-Focused Outcomes; Patients; Peripheral arterial disease; Pharmaceutical Preparations; Physicians; Population; Predisposition; Randomized; Randomized Clinical Trials; Randomized Controlled Clinical Trials; Reporting; Savings; Scientist; Single-Blind Study; Site; Skin Substitutes; System; Temperature; Testing; Tissue Engineering; Tissues; Ulcer; Weight-Bearing state; Work; Wound Healing; angiogenesis; arm; base; comparative efficacy; cost; cost effective; cytokine; diabetic; diabetic wound healing; effective therapy; experience; extracellular; foot; genetic signature; healing; improved; keratinocyte; new growth; novel therapeutics; patient population; predictive marker; secondary outcome; standard of care; treatment duration; wound

DESCRIPTION (provided by applicant): Chronic, non-healing ulcers of the feet are common complications of adults with diabetes, occurring in about 15-20% of diabetics, and often leading to foot amputation. The resulting diabetic foot ulcers (DFU) and subsequent amputations generate significant patient morbidity and millions of dollars of health care expenditures. Even with the best standard of care, which is debridement of non-viable tissue, off-loading of weight-bearing and treatment of infection, only 30% of diabetic foot ulcers can be expected to heal within a 20 week treatment period. There is clearly an unmet need for better and more effective treatments to improve healing of these ulcers. New therapies are limited, but among them are bioengineered skin substitutes that incorporate elements of an extracellular matrix that is proposed to encourage angiogenesis and in-growth of new tissue, along with living cells, to generate the cytokines needed for wound repair. However the cost of engineered tissue can be staggering: $1,800 per application, and 8 applications required-to achieve the 50% healing rate noted in the clinical trials. We note that other biological tissues have also been shown to be effective in improving the rate of healing of diabetic ulcers, and these tissues, devoid of living cells and simpler to prepare for use, have also been found to be effective in healing ulcers with reported similar increased rates compared to standard of care. These non-cellular tissues however, are orders of magnitude cheaper than bioengineered tissues. We hypothesize that there is no difference in efficacy between these two product types, and that using the less expensive matrix could save our health care system millions of dollars without compromising patient health. Our goal in this proposal is to test this hypothesis using a randomized clinical trial. We propose a randomized, single blinded, clinical trial with four arms: standard of care, standard of care plus Dermagraft(R) (bioengineered extracellular matrix containing living fibroblasts), standard of care plus Apligraf(R) (bioengineered extracellular bilayered matrix containing living keratinocytes and fibroblasts), standard of care plus Oasis(R) (Healthpoint, Ltd.), extracellular matrix devoid of living cells in patients with non-healing diabetic foot ulcers. We plan to determine: Specific Aim 1: Effectiveness of each treatment arm in achieving the primary endpoint of wound closure at 12 weeks and secondary outcomes of complete closure at 20 weeks, and rate of healing in each treatment arm. Specific Aim 2: Cost analysis to determine which bioengineered extracellular matrix for the treatment of diabetic foot ulcers is most cost effective in reducing healthcare costs. Specific Aim 3: The genetic signature of non-healing vs. healing diabetic ulcers to identify biomarkers predictive for a wound that will heal within 12-20 weeks of treatment. Our work could provide not only important savings to our health care system, but also improved access to limb and life saving therapies for healing DFU to millions of affected individuals.

描述(由申请人提供)： 慢性、无法愈合的足部溃疡是成人糖尿病患者的常见并发症，约有15%-20%的糖尿病患者会出现，并经常导致足部截肢。由此导致的糖尿病足部溃疡(DFU)和随后的截肢会导致患者的严重发病率和数百万美元的医疗保健支出。即使有最好的护理标准，即清创不可存活的组织，减轻负担和治疗感染，也只有30%的糖尿病足部溃疡有望在20周的治疗期内痊愈。显然，对更好、更有效的治疗方法的需求尚未得到满足，以促进这些溃疡的愈合。新的治疗方法是有限的，但其中包括生物工程皮肤替代品，它含有细胞外基质的成分，旨在鼓励血管生成和新组织的内生长，以及活细胞，以产生伤口修复所需的细胞因子。然而，工程组织的成本可能是惊人的：每个应用程序1800美元，需要8个应用程序-以实现临床试验中提到的50%的愈合率。我们注意到，其他生物组织也被证明在提高糖尿病溃疡的愈合率方面是有效的，这些组织缺乏活细胞，更容易准备使用，也被发现在愈合溃疡方面有效，报告的比率与标准护理相比有类似的提高。然而，这些非细胞组织比生物工程组织便宜了几个数量级。我们假设这两种产品的疗效没有差别，使用较便宜的矩阵可以在不损害患者健康的情况下为我们的医疗保健系统节省数百万美元。我们在这项提案中的目标是使用随机临床试验来检验这一假说。我们建议进行一项随机、单盲的临床试验，试验分为四个部分：标准护理、标准护理加DERMAGRAFT(R)(含有活的成纤维细胞的生物工程细胞外基质)、标准护理加Apligraf(R)(含有活的角质形成细胞和成纤维细胞的生物工程细胞外双层基质)、标准护理加OASIS(R)(Healthpoint，Ltd.)、无活细胞的细胞外基质治疗未愈合的糖尿病足部溃疡患者。我们计划确定：具体目标1：每个治疗臂在12周达到伤口闭合的主要终点和在20周达到完全闭合的次要结果的有效性，以及每个治疗臂的愈合率。具体目标2：成本分析，以确定哪种生物工程细胞外基质用于治疗糖尿病足部溃疡在降低医疗成本方面最具成本效益。具体目标3：未愈合的糖尿病溃疡与治愈的糖尿病溃疡的遗传特征，以确定预测伤口将在治疗后12-20周内愈合的生物标志物。我们的工作不仅可以为我们的医疗保健系统提供重要的节省，还可以改善获得肢体和挽救生命的治疗方法，以治愈数百万受影响的DFU患者。